Future Fund LLC Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Future Fund LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 61.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 74,973 shares of the biopharmaceutical company’s stock after buying an additional 28,433 shares during the period. Future Fund LLC’s holdings in Catalyst Pharmaceuticals were worth $1,750,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Intech Investment Management LLC lifted its position in shares of Catalyst Pharmaceuticals by 27.6% in the 4th quarter. Intech Investment Management LLC now owns 69,447 shares of the biopharmaceutical company’s stock worth $1,621,000 after purchasing an additional 15,034 shares during the period. Geode Capital Management LLC lifted its position in shares of Catalyst Pharmaceuticals by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 2,900,337 shares of the biopharmaceutical company’s stock worth $67,704,000 after purchasing an additional 10,017 shares during the period. Steel Grove Capital Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $206,000. Jackson Creek Investment Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $463,000. Finally, AlphaQuest LLC lifted its position in shares of Catalyst Pharmaceuticals by 103.5% in the 4th quarter. AlphaQuest LLC now owns 130,106 shares of the biopharmaceutical company’s stock worth $3,037,000 after purchasing an additional 66,169 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 0.2%

NASDAQ:CPRX opened at $31.23 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56. The firm has a 50 day moving average of $27.62 and a 200 day moving average of $25.03. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of 17.95, a PEG ratio of 0.95 and a beta of 0.72.

Analyst Ratings Changes

Several brokerages have recently weighed in on CPRX. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Finally, Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).